NasdaqGS:CMPSBiotechs
A Look At COMPASS Pathways (CMPS) Valuation After Positive COMP360 Phase 3 Results And FDA Plans
Why COMPASS Pathways is back on investor radar
COMPASS Pathways (NasdaqGS:CMPS) has attracted fresh attention after reporting highly statistically significant, clinically meaningful Phase 3 results for its COMP360 psilocybin therapy in treatment resistant depression, along with plans to seek a rolling FDA review.
See our latest analysis for COMPASS Pathways.
The latest COMP360 data and follow on offering come after a sharp 50.96% 90 day share price return and a 112.16% 1 year total...